Jeffrey Newcorn
Child & Adolescent Psychiatry · New York, NYNPI 1790985240
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $101,855 of the $164,758 with a category attached, or 61.8%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2019 at $54,881 and has fallen 86.7% since, to $7,277 in 2025. Among child & adolescent psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $1152.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$39K
- Shire North American Group Inc$34K
- Supernus Pharmaceuticals, Inc.$22K
- Adlon Therapeutics L.p.$20K
- Arbor Pharmaceuticals, Inc.$15K
- Ironshore Pharmaceuticals Inc.$12K
- plus $24K from 8 others
Across 51 payments — averaging $5911.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Purdue Pharma L.p.$138K
- Supernus Pharmaceuticals, Inc.$88K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$66K
- Collegium Pharmaceutical, Inc.$9K
What the payments were for
- Consulting fees$101,85562%
- Speaking & faculty fees$24,06815%
- Travel & lodging$24,87615%
- Food & beverage$4,8743%
- Education$9,0856%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 23 | $39,033 |
| Shire North American Group Inc | 34 | $33,805 |
| Supernus Pharmaceuticals, Inc. | 24 | $21,714 |
| Adlon Therapeutics L.p. | 7 | $19,692 |
| Arbor Pharmaceuticals, Inc. | 8 | $15,060 |
| Ironshore Pharmaceuticals Inc. | 19 | $11,660 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $9,526 |
| Eisai Inc. | 9 | $3,603 |
| Sunovion Pharmaceuticals Inc. | 1 | $3,400 |
| Rhodes Pharmaceuticals L.p. | 1 | $2,700 |
| Corium, LLC | 2 | $2,340 |
| H. Lundbeck A S | 1 | $1,600 |
| Tris Pharma Inc | 8 | $563 |
| Collegium Pharmaceutical, Inc. | 1 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTUNIV$20,240
- ADHANSIA XR$19,692
- QELBREE$17,001
- Evekeo$7,630
- JORNAY PM$6,746
- MYDAYIS$4,195
- Jornay PM 20mg capsules (Bottle of 100)$4,193
- Dayvigo$3,302
- Azstarys$2,340
- Evekeo ODT$2,188
- Dyanavel XR$259
How this compares
$164,758 in reported general payments places this provider in the 95th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Depakote SprinkleDivalproex Sodium | 13 | $6,604 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 29 | $595 |
| Risperidone | 13 | $462 |
| Hydroxyzine Hcl | 12 | $248 |
| Trazodone Hcl | 13 | $234 |
| Quetiapine Fumarate | 25 | $186 |
| Clonidine Hcl | 13 | $115 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in New York
- Matthew LorberNew York$398K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Alexander KolevzonNew York$10K
- Moira RynnNew York$8K
- Jeremy Veenstra-VanderweeleNew York$7K
- Eric AlceraNew York$6K
- Adam CohenNew York$3K
- Philip VincentNew York$2K
- Shannon DelaneyNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.